Compare RCKT & CRGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCKT | CRGY |
|---|---|---|
| Founded | 1999 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.9M | 2.3B |
| IPO Year | N/A | N/A |
| Metric | RCKT | CRGY |
|---|---|---|
| Price | $3.89 | $7.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $29.12 | $14.10 |
| AVG Volume (30 Days) | 2.0M | ★ 5.9M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 5.98% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | N/A | ★ $3,590,024,000.00 |
| Revenue This Year | N/A | $28.94 |
| Revenue Next Year | N/A | $24.77 |
| P/E Ratio | ★ N/A | $77.32 |
| Revenue Growth | N/A | ★ 32.31 |
| 52 Week Low | $2.19 | $6.83 |
| 52 Week High | $13.30 | $16.94 |
| Indicator | RCKT | CRGY |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 32.14 |
| Support Level | $3.36 | $7.88 |
| Resistance Level | $3.64 | $8.86 |
| Average True Range (ATR) | 0.20 | 0.31 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 82.56 | 5.51 |
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.